Bolt Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
BOLT$6.30-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for the
CONDENSED CONSOLIDATED STATEMENTS OFSTOCKHOLDERS’ EQUITY
(Unaudited, in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at March 31, 2026 | 1,921,567 | $— | $487,856 | $(11) | $(468,023) | $19,822 |
| Issuance of common stock under employee stock purchase plan | 4,778 | — | 19 | — | — | 19 |
| Stock-based compensation | — | — | 552 | — | — | 552 |
| Unrealized loss on available-for-sale investments | — | — | — | (33) | — | (33) |
| Net loss | — | — | — | — | (7,720) | (7,720) |
| Balance at June 30, 2026 | 1,926,345 | $— | $488,427 | $(44) | $(475,743) | $12,640 |
| Accumulated | ||||||
| Additional · Other · Total | ||||||
| Common · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at March 31, 2025 | 1,916,943 | $— | $485,213 | $40 | $(438,443) | $46,810 |
| Issuance of common stock under employee stock purchase plan | 2,498 | — | 14 | — | — | 14 |
| Stock-based compensation | — | — | 625 | — | — | 625 |
| Unrealized loss on available-for-sale investments | — | — | — | (46) | — | (46) |
| Net loss | — | — | — | — | (8,561) | (8,561) |
| Balance at June 30, 2025 | 1,919,441 | $— | $485,852 | $(6) | $(447,004) | $38,842 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited, in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at December 31, 2025 | 1,920,566 | $— | $487,305 | $(21) | $(460,779) | $26,505 |
| Issuance of common stock under employee stock purchase plan | 4,778 | — | 19 | — | — | 19 |
| Issuance of common stock upon exercise of stock options | 1,001 | — | 6 | — | — | 6 |
| Stock-based compensation | — | — | 1,097 | — | — | 1,097 |
| Unrealized loss on available-for-sale investments | — | — | — | (23) | — | (23) |
| Net loss | — | — | — | — | (14,964) | (14,964) |
| Balance at June 30, 2026 | 1,926,345 | $— | $488,427 | $(44) | $(475,743) | $12,640 |
| Accumulated | ||||||
| Additional · Other · Total | ||||||
| Common · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2024 | 1,916,943 | $— | $484,504 | $97 | $(427,403) | $57,198 |
| Issuance of common stock under employee stock purchase plan | 2,498 | — | 14 | — | — | 14 |
| Stock-based compensation | — | — | 1,334 | — | — | 1,334 |
| Unrealized loss on available-for-sale investments | — | — | — | (103) | — | (103) |
| Net loss | — | — | — | — | (19,601) | (19,601) |
| Balance at June 30, 2025 | 1,919,441 | $— | $485,852 | $(6) | $(447,004) | $38,842 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.